Amgen Inc (AMGN) operating KPIs
AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)
Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%
Latest, FY2015
-111
Period ended Dec 31, 2015
Change on a year earlier
-227.6%
87 in FY2014
History
9 years
Since FY2007
Sources
7
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Impairment charges ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2015 | Dec 31, 2015 | -111 | -227.6% | Form 10-K (filed 2016-02-16) ↗ |
| FY2014 | Dec 31, 2014 | 87 | +357.9% | Form 10-K (filed 2015-02-19) ↗ |
| FY2013 | Dec 31, 2013 | 19 | -89.3% | Form 10-K (filed 2014-02-24) ↗ |
| FY2012 | Dec 31, 2012 | 178 | +2,866.7% | Form 10-K (filed 2013-02-27) ↗ |
| FY2011 | Dec 31, 2011 | 6 | -94.9% | Form 10-K (filed 2012-02-29) ↗ |
| FY2010 | Dec 31, 2010 | 118 | +461.9% | Form 10-K (filed 2011-02-25) ↗ |
| FY2009 | Dec 31, 2009 | 21 | -64.4% | Form 10-K (filed 2010-03-01) ↗ |
| FY2008 | Dec 31, 2008 | 59 | -85.4% | Form 10-K (filed 2010-03-01) ↗ |
| FY2007 | Dec 31, 2007 | 404 | – | Form 10-K (filed 2010-03-01) ↗ |
Cite this data
StockData. (2026). Amgen Impairment charges ($M) ($M), annual FY2007–FY2015 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/fs_impair
See every metric in the Amgen KPI table. Data updated Oct 28, 2026.